The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable results

被引：0
|
作者：
Sagar, R. [1 ]
Lenti, M. [1 ]
Clark, T. [1 ]
Rafferty, H. [1 ]
Gracie, D. [1 ]
Ford, A. [1 ]
O'Connor, A. [1 ]
Hamlin, J. [1 ]
Ahmad, T. [2 ]
Selinger, C. [1 ]
机构：
[1] St James Univ Hosp, Gastroenterol, Leeds, W Yorkshire, England
[2] Royal Devon & Exeter Fdn Trust, Gastroenterol, Exeter, Devon, England
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P737
引用
收藏
页码：S484 / S485
页数：3
相关论文
共 50 条
  • [1] INFLIXIMAB THERAPEUTIC DRUG MONITORING IN IBD VIRTUAL BIOLOGICS CLINIC LEADS TO DURABLE RESULTS
    Selinger, Christian
    Lenti, Marco
    Clark, Tanya
    Rafferty, Helen
    Gracie, David
    Ford, Alex
    O'Connor, Anthony
    Ahmad, Tariq
    Hamlin, John
    Sagar, Rebecca
    GUT, 2018, 67 : A94 - A94
  • [2] THE IMPACT OF INFLIXIMAB THERAPEUTIC DRUG MONITORING ON DECISIONS MADE IN A VIRTUAL BIOLOGICS CLINIC FOR INFLAMMATORY BOWEL DISEASE
    Selinger, C. P.
    Lenti, M. V.
    Clark, T.
    Rafferty, H.
    O'Connor, A.
    Ahmad, T.
    Hamlin, P. J.
    DIGESTIVE AND LIVER DISEASE, 2017, 49 : E202 - E202
  • [3] Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease
    Selinger, Christian P.
    Lenti, Marco V.
    Clark, Tanya
    Rafferty, Helen
    Gracie, David
    Ford, Alexander C.
    O'Connor, Anthony
    Ahmad, Tariq
    Hamlin, P. John
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (12) : 2083 - 2088
  • [4] The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD
    Selinger, C.
    Lenti, M.
    Clark, T.
    Rafferty, H.
    O'Connor, A.
    Ahmad, T.
    Hamlin, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S411 - S412
  • [5] THE IMPACT OF INFLIXIMAB (IFX) THERAPEUTIC DRUG MONITORING ON DECISIONS MADE IN A VIRTUAL BIOLOGICS CLINIC FOR IBD
    Selinger, C.
    Lenti, M.
    Clark, T.
    Rafferty, H.
    O'Connor, A.
    Ahmad, T.
    Hamlin, J.
    GUT, 2017, 66 : A148 - A148
  • [6] Therapeutic drug monitoring of biologics for inflammatory bowel disease
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Sandborn, William J.
    Van Assche, Gert
    Robinson, Anne M.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (02) : 349 - 358
  • [7] Proactive therapeutic drug monitoring of infliximab leads to durability of treatment in children with Inflammatory Bowel Disease
    Chuah, C. W.
    Eldredge, J.
    Magoffin, A.
    O'Loughlin, E., V
    Park, C. J.
    Puppi, J.
    Siew, S.
    Stormon, M.
    Thacker, K.
    Dutt, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2099 - i2099
  • [8] Proactive therapeutic drug monitoring (TDM) of infliximab leads to durability of treatment in children with inflammatory bowel disease
    Chuah, Cher Wei
    Dutt, Shoma
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 325 - 325
  • [9] Prospective Therapeutic Drug Monitoring to Optimizing Infliximab (IFX) Maintenance Therapy in Patients With Inflammatory Bowel Disease (IBD)
    Vaughn, Byron P.
    Martinez-Vazquez, Manuel
    Patwardhan, Vilas
    Moss, Alan C.
    Sandborn, William J.
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2014, 146 (05) : S54 - S54
  • [10] Audit and review of infliximab therapeutic drug monitoring and prescribing practices in paediatric inflammatory bowel disease (IBD) patients
    Lang, C.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S264 - S264
12345